An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

NCT00806546 | Completed Phase 3 Results

• 1 other identifier: PROT-15-NP101-009
• Study Type: interventional
• Target: 514
• Locations: 1 country
• Sites: 31

Brief Summary

This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.

Conditions

Migraine Disorders

Outcome Measures

Primary Outcomes (1)

• Subject Self-examination of Skin Irritation

  For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin).

  24 hours post patch application

Study Arms (1)

NP101

EXPERIMENTAL

sumatriptan iontophoretic transdermal patch

Drug: NP101

Interventions

NP101 DRUG

NP101 study patch four hour application

NP101

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is an adult male or female, age range 18 years to 65 years.
• Subject has a diagnosis of migraine headache, with or without aura, as defined in the ICHD-II and the diagnosis was made before the age of 50.
• Subject experiences mild to severe headaches during a migraine attack based on subject testimony.
• Subject has at least a one year history of migraine based upon subject testimony.
• Subject typically experiences at least two migraine headaches per month based on subject testimony.
• Subject will be judged to be in good health, based upon the results of a medical history, physical examination, vital signs, ECG and laboratory profile. Subjects will not have any clinically significant abnormal laboratory parameters, vital signs or ECG parameters in order to qualify for enrollment.
• Female subject of childbearing potential (not surgically sterile or 2 years postmenopausal) must have a negative pregnancy test at screening and prior to enrollment.
• Subject must have a negative drug screen.
• Subject must be capable of reading and understanding either English or Spanish subject information materials. Be able to successfully apply a practice patch, carry-out all subject procedures, and be able to voluntarily sign and date an IC agreement approved by an IRB.
• Subject has at least two acceptable patch application sites (upper arms or upper thighs) that are relatively hair free and has no scars, tattoos, scratches or bruises.
• In the investigator's opinion the subject is on a stable medication regimen.

You may not qualify if:

• Subject has more than 15 headache days per month for any of the three months prior to screening.
• Subject has suspected or confirmed cardiovascular disease that contraindicates study participation.
• Subject has a history of epilepsy or condition associated with a lowered seizure threshold.
• Subject has Raynaud's disease.
• Subject has a history of basilar or hemiplegic migraines.
• Subject has a history (within 1 year) or current evidence of drug or alcohol abuse or dependence.
• Subject has taken non-triptan serotonergic drugs including SSRIs (including Wellbutrin), SNRIs, TCAs, MAOIs or preparations containing St. John's Wort within 1 month prior to screening and/or is planning to start any of these medications during the study.
• Subject is unwilling to discontinue use of a PD5 inhibitor (e.g. Viagra®, Levitra®, or Cialis®) through the Final Visit.
• Subject has a history of a significant allergy or hypersensitivity to any component of the study patch used in this study.
• Subject has any generalized skin irritation or disease including eczema, psoriasis, melanoma, or contact dermatitis that would affect transdermal absorption of sumatriptan and / or affect the subjects ability to assess skin irritation.
• Subject has clinically significant abnormal laboratory parameters, vital signs or ECG parameters.
• Subject is known to be hepatitis B, hepatitis C or HIV positive.
• Subject has a diagnosis of bipolar disorder or current major depressive disorder, or has any other medical or psychiatric condition, that in the investigator's opinion would make the subject unsuitable for enrollment / participation in the study.
• Subject has hepatic dysfunction defined as SGOT/AST or SGPT/ALT ≥ 2 times the upper limit of normal (ULN) range, or alkaline phosphatase or total bilirubin ≥ 1.5 times the ULN range or if in the opinion of the Investigator the subject's history, physical examination or other laboratory tests suggest hepatic dysfunction.
• Female subject who is pregnant, breast feeding, or if of childbearing potential, is not using or is unwilling to use an effective form of contraception during the study and for a period of 30 days following dosing.

Sponsors & Collaborators

• NuPathe Inc.: lead

Study Sites (31)

Unknown Facility

Phoenix, Arizona, United States

Location

Unknown Facility

Scottsdale, Arizona, United States

Location

Unknown Facility

Irvine, California, United States

Location

Unknown Facility

Newport Beach, California, United States

Location

Unknown Facility

San Francisco, California, United States

Location

Unknown Facility

Santa Monica, California, United States

Location

Unknown Facility

Walnut Creek, California, United States

Location

Unknown Facility

Fairfield, Connecticut, United States

Location

Unknown Facility

Hallandale, Florida, United States

Location

Unknown Facility

Ocala, Florida, United States

Location

Unknown Facility

Sunrise, Florida, United States

Location

Unknown Facility

Atlanta, Georgia, United States

Location

Unknown Facility

Decatur, Georgia, United States

Location

Unknown Facility

Savannah, Georgia, United States

Location

Unknown Facility

Crestview Hills, Kentucky, United States

Location

Unknown Facility

Ann Arbor, Michigan, United States

Location

Unknown Facility

St Louis, Missouri, United States

Location

Unknown Facility

Mount Vernon, New York, United States

Location

Unknown Facility

Plainview, New York, United States

Location

Unknown Facility

Greensboro, North Carolina, United States

Location

Unknown Facility

Cincinnati, Ohio, United States

Location

Unknown Facility

Cleveland, Ohio, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, United States

Location

Unknown Facility

Clarksville, Tennessee, United States

Location

Unknown Facility

Dallas, Texas, United States

Location

Unknown Facility

San Antonio, Texas, United States

Location

Unknown Facility

Alexandria, Virginia, United States

Location

Unknown Facility

Virginia Beach, Virginia, United States

Location

Unknown Facility

Seattle, Washington, United States

Location

MeSH Terms

Conditions

Migraine Disorders

Condition Hierarchy (Ancestors)

Headache Disorders, Primary; Headache Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Results Point of Contact

• Title: Mark Pierce, MD, PhD
• Organization: NuPathe Inc.

mpierce@nupathe.com

484-567-0130

Study Officials

• Mark Pierce, M.D., PhD.

  NuPathe Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 10, 2008
• First Posted: December 11, 2008
• Study Start: February 1, 2009
• Primary Completion: May 1, 2011
• Study Completion: May 1, 2011
• Last Updated: February 4, 2016
• Results First Posted: March 20, 2013

Record last verified: 2016-02

Locations

US (31)